Update on autoimmune hepatitis

被引:37
作者
Teufel, Andreas [2 ]
Galle, Peter R. [2 ]
Kanzler, Stephan [1 ]
机构
[1] Leopoldina Hosp, Dept Med 2, D-97422 Schweinfurt, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Med 1, D-55099 Mainz, Germany
关键词
Autoimmune hepatitis; Autoimmune liver disease; Budesonide; Genetics; Mycophenolate mofetil; Overlap syndromes; CHRONIC ACTIVE HEPATITIS; REGULATORY T-CELLS; MYCOPHENOLATE-MOFETIL; IMMUNOSUPPRESSIVE THERAPY; BUDESONIDE; TYPE-1; REMISSION; SUSCEPTIBILITY; ASSOCIATION; MAINTENANCE;
D O I
10.3748/wjg.15.1035
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology that occurs in children and adults of all ages. Characteristics are its autoimmune features, hyperglobulinemia (IgG), and the presence of circulating autoantibodies, as well as a response to immunosuppressant drugs. Current treatment consists of prednisone and azathioprine and in most patients this disease has become very treatable. Over the past 2 years, a couple of new insights into the genetic aspects, clinical course and treatment of AIH have been reported, which will be the focus of this review. In particular, we concentrate on genome-wide microsatellite analysis, a novel mouse model of AIH, the evaluation of a large AIH cohort for overlap syndromes, suggested novel criteria for the diagnosis of AIH, and the latest studies on treatment of AM with budenoside and mycophenolate mofetil. (C) 2009 The WJG Press and Baishideng. All rights reserved.
引用
收藏
页码:1035 / 1041
页数:7
相关论文
共 47 条
[1]
A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis [J].
Agarwal, K. ;
Czaja, A. J. ;
Donaldson, P. T. .
TISSUE ANTIGENS, 2007, 69 (03) :227-235
[2]
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis [J].
Agarwal, K ;
Czaja, AJ ;
Jones, DEJ ;
Donaldson, PT .
HEPATOLOGY, 2000, 31 (01) :49-53
[3]
International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[4]
Short-term cyclosporine induces a remission of autoimmune hepatitis in children [J].
Alvarez, F ;
Ciocca, M ;
Cañero-Velasco, C ;
Ramonet, M ;
de Davila, MTG ;
Cuarterolo, M ;
Gonzalez, T ;
Jara-Vega, P ;
Camarena, C ;
Brochu, P ;
Drut, R ;
Alvarez, E .
JOURNAL OF HEPATOLOGY, 1999, 30 (02) :222-227
[5]
Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate [J].
Burak, KW ;
Urbanski, SJ ;
Swain, MG .
JOURNAL OF HEPATOLOGY, 1998, 29 (06) :990-993
[6]
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus [J].
Chatur, N ;
Ramji, A ;
Bain, VG ;
Ma, MM ;
Marotta, PJ ;
Ghent, CN ;
Lilly, LB ;
Heathcote, EJ ;
Deschenes, M ;
Lee, SS ;
Steinbrecher, UP ;
Yoshida, EM .
LIVER INTERNATIONAL, 2005, 25 (04) :723-727
[7]
Variant forms of autoimmune hepatitis. [J].
Czaja A.J. .
Current Gastroenterology Reports, 1999, 1 (1) :63-70
[8]
Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial [J].
Czaja, AJ ;
Carpenter, HA ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1381-1386
[9]
Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis [J].
Czaja, AJ ;
Lindor, KD .
GASTROENTEROLOGY, 2000, 119 (05) :1312-1316
[10]
DANIELSSON A, 1994, ALIMENT PHARM THERAP, V8, P585